Abstract:Background: Aspirin is a frequently prescribed drug for primary and secondary prevention of myocardial infarction, stroke and cardiovascular death. However, aspirin resistance may affect up to 45% of the population. Little is known on the role of genetic factors that contribute to resistance or augmented response to aspirin in different human populations. Methods: In a large sample of nonsmoker, medication-free healthy volunteers from mainland China (n = 323; age: 22.1 +/- 2.0 years) (mean standard deviation), we determined the frequency of polymorphisms in cyclooxygenase 1 (COX1) (A-842G and C50T), glycoprotein IIIa (GPIIIa) (PLA1/A2) and purinergic receptor P2Y (P2Y1) (C893T and A1622G) genes. These candidate genes were chosen on the basis of their impact on platelet physiology and aspirin mode of action. A four panel P2Y1 genotype-stratified sample of healthy volunteers (n = 24 in total), identified from the large study sample above, prospectively received a 100 mg daily oral dose of aspirin for 7 days. We measured changes in platelet aggregation before and after aspirin treatment. As a comparison reference group, 6 out of 24 subjects in the prospective aspirin trial had the P2Y1 CT893/AG1622 genotype that displays a low frequency (< 7%) in the Chinese population. Results: COX1 A-842G, C50T and GPIIIa PLAVA2 genetic polymorphisms were not observed in our sample from mainland China. Allele frequencies of P2Y1 893T and 1622G were 3.5 and 30.6%, respectively. The heterozygosity for the P2YI A1622G polymorphism observed in the present study was different to Caucasians; Chinese displayed a higher allele frequency for the 1622G allele. After aspirin treatment, the net decrease in arachiclonic acid-induced platelet aggregation was significantly larger in the P2Y1 CT893/AG1622 genotype panel (83.4 +/- 3.7%, net reduction by aspirin expressed as percentage of baseline) compared with CC893/GG1622 (68.2 +/- 13.5%), CC893/AG1622 (68.9 +/- 9.6%) and CC893/AA1622 (65.1 +/- 9.1 %) genotypic groups (p = 0.012, 0.025 and 0.004, respectively; statistical power = 77%). There was no significant difference in antiplatelet effect of aspirin among the CC893/GG1622, CC893/AG1622 and CC893/AA1622 genotypes (p > 0.05). Conclusions: The COX1 A-842G, C50T and GPIIIa PLAVA2 polymorphisms are rare in Chinese. In contrast to previous studies in Caucasian populations, these candidate functional polymorphisms are unlikely to be significant contributors to aspirin pharmacodynamics in Chinese persons. Importantly, the presence of the P2YI 893CC genotype appears to confer an attenuated antiplatelet effect during aspirin treatment in healthy Chinese volunteers. These data collectively underscore the importance of population-to-population variability in clinical pharmacogenetics research and provide a basis for further long-term studies of aspirin response and P2Y1 genetic variation in patients with cardiovascular risk.

IDENTIFICATION OF ASPIRIN RESPONSE RELATED GENE PROFILES IN THE ELDERLY POPULATION WITH CORONARY ARTERY DISEASE

Aspirin Resistance in the Elder Cardio-Cerebral-Vascular Diseases Patients

ASSA14-03-38 Comparison of Urinary11-DehydrothromboxaneB2 detection and Plasma LTA Assay for evaluating aspirin response in the Aged Patients with Coronary Artery Disease

Validation of Aspirin Response-Related Transcripts in Patients with Coronary Artery Disease and Preliminary Investigation on CMTM5 Function.

Comparison Between Urinary 11-Dehydrothromboxane B2 Detection and Platelet Light Transmission Aggregometry (lta) Assays for Evaluating Aspirin Response in Elderly Patients with Coronary Artery Disease

Genetic factors related to aspirin resistance using the Multiplate® device in Hong Kong Chinese patients with stable coronary heart disease

The Prevalence, Risk Factors and Prognosis of Aspirin Resistance in Elderly Male Patients with Cardiovascular Disease

ASSA14-03-42 Urinary 11-dehydro-Thromboxane B2 (11dhTxB2) and aspirin response in aged patients with coronary artery disease

Correlative Analysis of Aspirin Resistance with Gender and Age in Elderly Patients with Coronary Heart Dis-ease Accompanied by Type 2 Diabetes

Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin.

Predictors of High On-Aspirin Platelet Reactivity in Elderly Patients with Coronary Artery Disease

The clinical and laboratory research on aspirin resistance in cardiovascular and cerebrovascular patients

Aspirin Response and Related Factors in Aged Patients

Aspirin Resistance: Clinical Significance and Genetic Polymorphism

Resistance of Acute Coronary Syndrome Patients to Antiplatelet Drugs and Its Correlation to COX-1 Gene

Association Between Renal Function and Platelet Reactivity During Aspirin Therapy in Elderly Patients with Atherosclerotic Cardiovascular Disease

[Aspirin Resistance in Patients Taking Small Dose of Aspirin].

Changes of Platelet Function after Antiplatelet Therapy and Single Nucleotide Polymorphism of COX-1 and COX-2 in Elderly Patients

Anti-aggregation Effect and Short-term Safety Evaluation of Low-dose Aspirin Therapy in the Elderly Chinese Population: a Multicenter Randomized Controlled Clinical Trial

Factors Influencing Aspirin Hyporesponsiveness In Elderly Chinese Patients

Correlations of P2Y1 and ITGB3 Polymorphisms with Aspirin Resistance in Patients with Large Artery Atherosclerotic Stroke